Almirall SA is a global biopharmaceutical company, which is focused on skin health. The company is headquartered in Barcelona, Barcelona and currently employs 2,084 full-time employees. The company went IPO on 2007-04-19. The firm focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The firm's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The firm operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Follow-Up Questions
Almirall SA의 CEO는 누구입니까?
Mr. Carlos Gallardo Pique은 2014부터 회사에 합류한 Almirall SA의 Executive Chairman of the Board입니다.
LBTSF 주식의 가격 성능은 어떻습니까?
LBTSF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Almirall SA의 주요 사업 주제나 업종은 무엇입니까?
Almirall SA은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Almirall SA의 시가총액은 얼마입니까?
Almirall SA의 현재 시가총액은 $0입니다
Almirall SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 15명의 분석가가 Almirall SA에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 9명의 매수, 3명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
